Bavencio Approval History
- FDA approved: Yes (First approved March 23rd, 2017)
- Brand name: Bavencio
- Generic name: avelumab
- Dosage form: Injection
- Company: EMD Serono, Inc.
- Treatment for: Merkel Cell Carcinoma; Urothelial Carcinoma
Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody
indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC) and urothelial carcinoma.
Development History and FDA Approval Process for Bavencio
|May 9, 2017|| FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma|
|Mar 23, 2017|| FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma|
|Feb 28, 2017||FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review|
|Nov 29, 2016||FDA Accepts the BLA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review|
|Jul 6, 2016||Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer|
|Jun 6, 2016||ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma|
|Jan 4, 2016||Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer|
|Nov 18, 2015||Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma|
|Nov 4, 2015||Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer|
|Apr 20, 2015||Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.